×
Chimerix Operating Expenses 2011-2024 | CMRX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Chimerix operating expenses from 2011 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
Chimerix Operating Expenses 2011-2024 | CMRX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Chimerix operating expenses from 2011 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$171.5B
Vertex Pharmaceuticals (VRTX)
$121.6B
Gilead Sciences (GILD)
$111.4B
Bristol Myers Squibb (BMY)
$110.2B
Regeneron Pharmaceuticals (REGN)
$93B
CSL (CSLLY)
$90B
GSK (GSK)
$76.4B
Argenex SE (ARGX)
$35.6B
Alnylam Pharmaceuticals (ALNY)
$35.3B
BioNTech SE (BNTX)
$26.5B
Biogen (BIIB)
$25.3B
Illumina (ILMN)
$23.9B
Moderna (MRNA)
$21B
BeiGene (BGNE)
$19.9B
Genmab (GMAB)
$14.9B
Incyte (INCY)
$14.7B
Exact Sciences (EXAS)
$12.9B
BioMarin Pharmaceutical (BMRN)
$12.7B
Vaxcyte (PCVX)
$12B
Bio-Techne Corp (TECH)
$11.9B
Sarepta Therapeutics (SRPT)
$11.8B
Insmed (INSM)
$11.7B
QIAGEN (QGEN)
$9.8B
Exelixis (EXEL)
$9.7B
Bio-Rad Laboratories (BIO.B)
$9.3B
Revolution Medicines (RVMD)
$9.2B
Intra-Cellular Therapies (ITCI)
$9.2B
Roivant Sciences (ROIV)
$8.6B
Viking Therapeutics (VKTX)
$8.1B
Legend Biotech (LEGN)
$8.1B